RedHill Biopharma (RDHL) Operating Margin: 2012-2023

Historic Operating Margin for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to 2,992.87%.

  • RedHill Biopharma's Operating Margin rose 322408.00% to 2,992.87% in Q2 2023 from the same period last year, while for Jun 2023 it was -122.98%, marking a year-over-year increase of 7662.00%. This contributed to the annual value of -181.69% for FY2024, which is 37513.00% down from last year.
  • RedHill Biopharma's Operating Margin amounted to 2,992.87% in Q2 2023, which was up 470.40% from -808.00% recorded in Q1 2023.
  • RedHill Biopharma's 5-year Operating Margin high stood at 2,992.87% for Q2 2023, and its period low was -808.00% during Q1 2023.
  • Its 3-year average for Operating Margin is 117.23%, with a median of 60.50% in 2021.
  • As far as peak fluctuations go, RedHill Biopharma's Operating Margin slumped by 152,314bps in 2021, and later soared by 322,408bps in 2023.
  • Over the past 5 years, RedHill Biopharma's Operating Margin (Quarterly) stood at 739.87% in 2019, then tumbled by 63,736bps to 102.51% in 2020, then plummeted by 74,395bps to -641.43% in 2021, then spiked by 4,962bps to -591.81% in 2022, then skyrocketed by 322,408bps to 2,992.87% in 2023.
  • Its Operating Margin was 2,992.87% in Q2 2023, compared to -808.00% in Q1 2023 and -591.81% in Q4 2022.